These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24803795)

  • 41. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis.
    Lv R; Qiao W; Wu Z; Wang Y; Dai S; Liu Q; Zheng X
    PLoS One; 2014; 9(1):e86692. PubMed ID: 24475168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
    Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
    Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Short-Term and Long-Term Outcomes of Infliximab and Tacrolimus Treatment for Moderate to Severe Ulcerative Colitis: Retrospective Observational Study.
    Otsuka T; Ooi M; Tobimatsu K; Wakahara C; Watanabe D; Adachi S; Yasutomi E; Yamairi H; Ku Y; Yoshida M; Hoshi N; Kodama Y
    Kobe J Med Sci; 2018 Dec; 64(4):E140-E148. PubMed ID: 30728340
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes?
    Mosli M; Alfaer S; Almalaki T; Albeshry A; Aljehani S; Alshmrani B; Habib Z; Jawa H; Qari Y
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):80-85. PubMed ID: 30199472
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
    Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
    J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
    Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
    World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a latin american referral population.
    Juliao F; Marquez J; Aristizabal N; Yepes C; Zuleta J; Gisbert JP
    Digestion; 2013; 88(4):222-8. PubMed ID: 24281150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis.
    Huang X; Lv B; Jin HF; Zhang S
    Eur J Clin Pharmacol; 2011 Aug; 67(8):759-66. PubMed ID: 21691804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.
    Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histological healing after infliximab induction therapy in children with ulcerative colitis.
    Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
    World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Anti-TNF-alpha therapy in ulcerative colitis].
    Lakatos PL; Lakatos L
    Orv Hetil; 2008 May; 149(20):921-7. PubMed ID: 18467261
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers.
    Tursi A; Allegretta L; Buccianti N; Della Valle N; Elisei W; Forti G; Faggiani R; Gallina S; Hadad Y; Larussa T; Lauria A; Luzza F; Lorenzetti R; Mocci G; Penna A; Polimeni N; Pranzo G; Ricciardelli C; Zampaletta C; Picchio M
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):239-244. PubMed ID: 28922435
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience.
    Laharie D; Filippi J; Roblin X; Nancey S; Chevaux JB; Hébuterne X; Flourié B; Capdepont M; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2013 May; 37(10):998-1004. PubMed ID: 23521659
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.
    Zhou YL; Xie S; Wang P; Zhang T; Lin MY; Tan JS; Zhi FC; Jiang B; Chen Y
    J Dig Dis; 2014 Sep; 15(9):483-90. PubMed ID: 24828856
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.
    Tursi A; Allegretta L; Chiri S; Della Valle N; Elisei W; Forti G; Lorenzetti R; Mocci G; Penna A; Pranzo G; Ricciardelli C; Picchio M
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):313-318. PubMed ID: 28293938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
    Zhou Z; Dai C; Liu WX
    Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study.
    Sjöberg M; Walch A; Meshkat M; Gustavsson A; Järnerot G; Vogelsang H; Hertervig E; Novacek G; Friis-Liby I; Blomquist L; Angelberger S; Karlen P; Grännö C; Vilien M; Ström M; Verbaan H; Hellström PM; Dejaco C; Magnuson A; Halfvarson J; Reinisch W; Tysk C
    Inflamm Bowel Dis; 2012 Feb; 18(2):212-8. PubMed ID: 21438096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
    Iborra M; Pérez-Gisbert J; Bosca-Watts MM; López-García A; García-Sánchez V; López-Sanromán A; Hinojosa E; Márquez L; García-López S; Chaparro M; Aceituno M; Calafat M; Guardiola J; Belloc B; Ber Y; Bujanda L; Beltrán B; Rodríguez-Gutiérrez C; Barrio J; Cabriada JL; Rivero M; Camargo R; van Domselaar M; Villoria A; Schuterman HS; Hervás D; Nos P;
    J Gastroenterol; 2017 Jul; 52(7):788-799. PubMed ID: 27722996
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.
    Taxonera C; Barreiro-de Acosta M; Calvo M; Saro C; Bastida G; Martín-Arranz MD; Gisbert JP; García-Sánchez V; Marín-Jiménez I; Bermejo F; Chaparro M; Ponferrada Á; Martínez-Montiel MP; Pajares R; de Gracia C; Olivares D; Alba C; Mendoza JL; Fernández-Blanco I
    Dig Dis Sci; 2015 Oct; 60(10):3075-84. PubMed ID: 26044830
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
    Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Savova G; Churchill S; Karlson EW; Kohane I; Liao KP; Murphy SN
    Inflamm Bowel Dis; 2016 Apr; 22(4):880-5. PubMed ID: 26933751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.